Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
Views & Analysis 2016 saw slump in FDA drug approvals, but 2017 could be retu... FDA approvals could rebound in 2017 - but concerns about big pharma R&D productivity won't go away.
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
Articles 10 drugs – and their prices – which changed pharma in 2015 In a record-breaking year for pharma, which drugs were the most outstanding?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.